By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801



Company News
Orexigen (OREX) Announces Submission Of Contrave New Drug Application In South Korea 10/1/2015 6:56:08 AM
Orexigen (OREX) Receives Payments Totaling $22 Million From U.S. And Korean Partners 9/23/2015 11:41:15 AM
Orexigen (OREX) Raises $60 Million In Sale Of Common Stock To Baupost 9/10/2015 11:42:30 AM
Orexigen (OREX) To Speak At The Wells Fargo Securities 2015 Healthcare Conference 9/4/2015 7:57:12 AM
Orexigen (OREX) Reports Financial And Business Results For The Second Quarter Ended June 30, 2015 8/6/2015 10:47:37 AM
Orexigen (OREX) Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical 8/6/2015 6:43:49 AM
Orexigen (OREX) And Takeda (TKPYY) Announce An Amended And Restated Collaboration Agreement 8/6/2015 6:40:10 AM
Orexigen (OREX) To Provide Business Update And Discuss Second Quarter 2015 Financial Results On August 6, 2015 7/24/2015 11:10:49 AM
Orexigen (OREX) To Speak At The JMP Securities Life Sciences Conference 6/18/2015 7:42:40 AM
Orexigen (OREX) Announces Upcoming Data Presentations From The Open-Label Contrave Ignite Study At The Annual Meeting Of The American Diabetes Association 6/5/2015 7:23:41 AM